ID   TRPM6_HUMAN             Reviewed;        2022 AA.
AC   Q9BX84; Q6VPR8; Q6VPR9; Q6VPS0; Q6VPS1; Q6VPS2;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 2.
DT   15-MAR-2017, entry version 137.
DE   RecName: Full=Transient receptor potential cation channel subfamily M member 6;
DE            EC=2.7.11.1;
DE   AltName: Full=Channel kinase 2;
DE   AltName: Full=Melastatin-related TRP cation channel 6;
GN   Name=TRPM6; Synonyms=CHAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND CHARACTERIZATION.
RC   TISSUE=Kidney;
RX   PubMed=11357414;
RA   Riazanova L.V., Pavur K.S., Petrov A.N., Dorovkov M.V., Riazanov A.G.;
RT   "Novel type of signaling molecules: protein kinases covalently linked
RT   to ion channels.";
RL   Mol. Biol. (Mosk.) 35:321-332(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND VARIANT HOMG1
RP   LEU-141.
RC   TISSUE=Kidney, and Small intestine;
RX   PubMed=12032568; DOI=10.1038/ng889;
RA   Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L.N.,
RA   Vitzthum H., Klingel K., Kratz M., Haddad E., Ristoff E., Dinour D.,
RA   Syrrou M., Nielsen S., Sassen M.C., Waldegger S., Seyberth H.W.,
RA   Konrad M.;
RT   "Hypomagnesemia with secondary hypocalcemia is caused by mutations in
RT   TRPM6, a new member of the TRPM gene family.";
RL   Nat. Genet. 31:166-170(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRPM6A; TRPM6B; TRPM6C; TRPM6T;
RP   M6-KINASE 1; M6-KINASE 2 AND M6-KINASE 3), CHARACTERIZATION OF VARIANT
RP   HOMG1 LEU-141, AND INTERACTION WITH TRPM7.
RC   TISSUE=Lung cancer;
RX   PubMed=14976260; DOI=10.1073/pnas.0305252101;
RA   Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H.,
RA   Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.;
RT   "Disruption of TRPM6/TRPM7 complex formation by a mutation in the
RT   TRPM6 gene causes hypomagnesemia with secondary hypocalcemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   INTERACTION WITH RACK1, PHOSPHORYLATION AT THR-1851, AND MUTAGENESIS
RP   OF LYS-1804 AND THR-1851.
RX   PubMed=18258429; DOI=10.1016/j.cub.2007.12.058;
RA   Cao G., Thebault S., van der Wijst J., van der Kemp A., Lasonder E.,
RA   Bindels R.J., Hoenderop J.G.;
RT   "RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha-
RT   kinase domain.";
RL   Curr. Biol. 18:168-176(2008).
RN   [6]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-75; ILE-338; CYS-1007; ARG-1243;
RP   ARG-1274; ILE-1393; GLU-1584; ARG-1663; SER-1673 AND ILE-1724.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [7]
RP   VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; PRO-1143 AND ASN-1754,
RP   VARIANT ARG-1663, CHARACTERIZATION OF VARIANTS HOMG1 PRO-708; GLY-872;
RP   CYS-1053; PRO-1143 AND ASN-1754, CHARACTERIZATION OF VARIANT ARG-1663,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=23942199; DOI=10.1038/ejhg.2013.178;
RA   Lainez S., Schlingmann K.P., van der Wijst J., Dworniczak B.,
RA   van Zeeland F., Konrad M., Bindels R.J., Hoenderop J.G.;
RT   "New TRPM6 missense mutations linked to hypomagnesemia with secondary
RT   hypocalcemia.";
RL   Eur. J. Hum. Genet. 22:497-504(2014).
CC   -!- FUNCTION: Essential ion channel and serine/threonine-protein
CC       kinase. Crucial for magnesium homeostasis. Has an important role
CC       in epithelial magnesium transport and in the active magnesium
CC       absorption in the gut and kidney. Isoforms of the type M6-kinase
CC       lack the ion channel region.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Forms heterodimers with TRPM7. TRPM6 requires the
CC       presence of TRPM7 to be targeted to the cell membrane (in HEK 293
CC       cells). Interacts (via kinase domain) with RACK1.
CC       {ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:18258429}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23942199};
CC       Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=TRPM6a;
CC         IsoId=Q9BX84-1; Sequence=Displayed;
CC       Name=TRPM6b;
CC         IsoId=Q9BX84-2; Sequence=VSP_012069;
CC       Name=TRPM6c;
CC         IsoId=Q9BX84-3; Sequence=VSP_012070;
CC       Name=TRPM6t;
CC         IsoId=Q9BX84-4; Sequence=VSP_012075, VSP_012076;
CC       Name=M6-kinase 1;
CC         IsoId=Q9BX84-5; Sequence=VSP_012074;
CC         Note=Lacks the ion channel region.;
CC       Name=M6-kinase 2;
CC         IsoId=Q9BX84-6; Sequence=VSP_012073;
CC         Note=Lacks the ion channel region.;
CC       Name=M6-kinase 3;
CC         IsoId=Q9BX84-7; Sequence=VSP_012071, VSP_012072;
CC         Note=Lacks the ion channel region.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in kidney and colon. Isoform
CC       TRPM6a and isoform TRPM6b, are coexpressed with TRPM7 in kidney,
CC       and testis, and are also found in several cell lines of lung
CC       origin. Isoform TRPM6c is detected only in testis and in NCI-H510A
CC       small cell lung carcinoma cells.
CC   -!- DISEASE: Hypomagnesemia 1 (HOMG1) [MIM:602014]: A disorder due to
CC       a primary defect in intestinal magnesium absorption. It is
CC       characterized by low levels of serum magnesium alongside with a
CC       normal renal magnesium secretion, secondary hypocalcemia and
CC       calcinocis. Affected individuals show neurologic symptoms of
CC       hypomagnesemic hypocalcemia, including seizures and muscle spasms,
CC       during infancy. Hypocalcemia is secondary to parathyroid failure
CC       resulting from magnesium deficiency. Untreated, the disorder may
CC       be fatal or may result in neurological damage.
CC       {ECO:0000269|PubMed:12032568, ECO:0000269|PubMed:14976260,
CC       ECO:0000269|PubMed:23942199}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the protein
CC       kinase superfamily. Alpha-type protein kinase family. ALPK
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the transient
CC       receptor (TC 1.A.4) family. LTrpC subfamily. TRPM6 sub-subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF350881; AAK31202.2; -; mRNA.
DR   EMBL; AF448232; AAM21562.1; -; mRNA.
DR   EMBL; AY333282; AAR03487.1; -; mRNA.
DR   EMBL; AY333283; AAR03488.1; -; mRNA.
DR   EMBL; AY333284; AAR03489.1; -; mRNA.
DR   EMBL; AY333285; AAR03490.1; -; mRNA.
DR   EMBL; AY333286; AAR03491.1; -; mRNA.
DR   EMBL; AY333287; AAR03492.1; -; mRNA.
DR   EMBL; AY333288; AAR03493.1; -; mRNA.
DR   EMBL; AL354795; CAH70894.1; -; Genomic_DNA.
DR   CCDS; CCDS55318.1; -. [Q9BX84-3]
DR   CCDS; CCDS55319.1; -. [Q9BX84-2]
DR   CCDS; CCDS6647.1; -. [Q9BX84-1]
DR   RefSeq; NP_001170781.1; NM_001177310.1. [Q9BX84-2]
DR   RefSeq; NP_001170782.1; NM_001177311.1. [Q9BX84-3]
DR   RefSeq; NP_060132.3; NM_017662.4. [Q9BX84-1]
DR   UniGene; Hs.272225; -.
DR   ProteinModelPortal; Q9BX84; -.
DR   SMR; Q9BX84; -.
DR   IntAct; Q9BX84; 3.
DR   MINT; MINT-6699468; -.
DR   STRING; 9606.ENSP00000354006; -.
DR   BindingDB; Q9BX84; -.
DR   ChEMBL; CHEMBL1628470; -.
DR   GuidetoPHARMACOLOGY; 498; -.
DR   TCDB; 1.A.4.5.8; the transient receptor potential ca(2+) channel (trp-cc) family.
DR   iPTMnet; Q9BX84; -.
DR   PhosphoSitePlus; Q9BX84; -.
DR   BioMuta; TRPM6; -.
DR   DMDM; 56404951; -.
DR   MaxQB; Q9BX84; -.
DR   PaxDb; Q9BX84; -.
DR   PeptideAtlas; Q9BX84; -.
DR   PRIDE; Q9BX84; -.
DR   Ensembl; ENST00000360774; ENSP00000354006; ENSG00000119121. [Q9BX84-1]
DR   Ensembl; ENST00000361255; ENSP00000354962; ENSG00000119121. [Q9BX84-3]
DR   Ensembl; ENST00000449912; ENSP00000396672; ENSG00000119121. [Q9BX84-2]
DR   GeneID; 140803; -.
DR   KEGG; hsa:140803; -.
DR   UCSC; uc004ajk.1; human. [Q9BX84-1]
DR   CTD; 140803; -.
DR   DisGeNET; 140803; -.
DR   GeneCards; TRPM6; -.
DR   H-InvDB; HIX0008102; -.
DR   HGNC; HGNC:17995; TRPM6.
DR   MalaCards; TRPM6; -.
DR   MIM; 602014; phenotype.
DR   MIM; 607009; gene.
DR   neXtProt; NX_Q9BX84; -.
DR   OpenTargets; ENSG00000119121; -.
DR   Orphanet; 30924; Primary hypomagnesemia with secondary hypocalcemia.
DR   PharmGKB; PA38479; -.
DR   eggNOG; ENOG410INBW; Eukaryota.
DR   eggNOG; ENOG410ZSH9; LUCA.
DR   GeneTree; ENSGT00760000119127; -.
DR   HOGENOM; HOG000230920; -.
DR   HOVERGEN; HBG055663; -.
DR   InParanoid; Q9BX84; -.
DR   KO; K04981; -.
DR   OMA; LMECMVH; -.
DR   OrthoDB; EOG091G0DHL; -.
DR   PhylomeDB; Q9BX84; -.
DR   TreeFam; TF314204; -.
DR   Reactome; R-HSA-3295583; TRP channels.
DR   GeneWiki; TRPM6; -.
DR   GenomeRNAi; 140803; -.
DR   PRO; PR:Q9BX84; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000119121; -.
DR   CleanEx; HS_TRPM6; -.
DR   ExpressionAtlas; Q9BX84; baseline and differential.
DR   Genevisible; Q9BX84; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005262; F:calcium channel activity; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB.
DR   Gene3D; 1.20.5.1010; -; 1.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR004166; MHCK_EF2_kinase.
DR   InterPro; IPR029597; TRPM6.
DR   InterPro; IPR032415; TRPM_tetra.
DR   PANTHER; PTHR13800:SF21; PTHR13800:SF21; 1.
DR   Pfam; PF02816; Alpha_kinase; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF16519; TRPM_tetra; 1.
DR   SMART; SM00811; Alpha_kinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51158; ALPHA_KINASE; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Calcium; Calcium channel;
KW   Calcium transport; Cell membrane; Complete proteome; Disease mutation;
KW   Ion channel; Ion transport; Kinase; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Primary hypomagnesemia; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Transmembrane;
KW   Transmembrane helix; Transport; Zinc.
FT   CHAIN         1   2022       Transient receptor potential cation
FT                                channel subfamily M member 6.
FT                                /FTId=PRO_0000215329.
FT   TOPO_DOM      1    741       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    742    762       Helical. {ECO:0000255}.
FT   TOPO_DOM    763    841       Extracellular. {ECO:0000255}.
FT   TRANSMEM    842    862       Helical. {ECO:0000255}.
FT   TOPO_DOM    863    905       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    906    926       Helical. {ECO:0000255}.
FT   TOPO_DOM    927    939       Extracellular. {ECO:0000255}.
FT   TRANSMEM    940    960       Helical. {ECO:0000255}.
FT   TOPO_DOM    961    972       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    973    993       Helical. {ECO:0000255}.
FT   TOPO_DOM    994   1012       Extracellular. {ECO:0000255}.
FT   INTRAMEM   1013   1033       Pore-forming. {ECO:0000255}.
FT   TOPO_DOM   1034   1047       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1048   1068       Helical. {ECO:0000255}.
FT   TOPO_DOM   1069   2022       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN     1750   1980       Alpha-type protein kinase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00501}.
FT   NP_BIND    1950   1956       ATP. {ECO:0000250}.
FT   ACT_SITE   1923   1923       Proton acceptor. {ECO:0000250}.
FT   METAL      1909   1909       Zinc. {ECO:0000250}.
FT   METAL      1966   1966       Zinc. {ECO:0000250}.
FT   METAL      1968   1968       Zinc. {ECO:0000250}.
FT   METAL      1972   1972       Zinc. {ECO:0000250}.
FT   BINDING    1780   1780       ATP. {ECO:0000250}.
FT   BINDING    1804   1804       ATP. {ECO:0000250}.
FT   BINDING    1876   1876       ATP. {ECO:0000250}.
FT   BINDING    1925   1925       ATP. {ECO:0000250}.
FT   BINDING    1933   1933       ATP. {ECO:0000250}.
FT   MOD_RES    1851   1851       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18258429}.
FT   VAR_SEQ       1     11       MKEQPVLERLQ -> MIILSK (in isoform
FT                                TRPM6b). {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012069.
FT   VAR_SEQ       1     11       MKEQPVLERLQ -> MTAPVT (in isoform
FT                                TRPM6c). {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012070.
FT   VAR_SEQ     281    281       R -> P (in isoform M6-kinase 3).
FT                                {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012071.
FT   VAR_SEQ     282   1734       Missing (in isoform M6-kinase 3).
FT                                {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012072.
FT   VAR_SEQ     500   1666       Missing (in isoform M6-kinase 2).
FT                                {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012073.
FT   VAR_SEQ     547   1595       Missing (in isoform M6-kinase 1).
FT                                {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012074.
FT   VAR_SEQ    1926   1943       GVGENLTDPSVIKPEVKQ -> ALWFWDSMLKARLGGWRM
FT                                (in isoform TRPM6t).
FT                                {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012075.
FT   VAR_SEQ    1944   2022       Missing (in isoform TRPM6t).
FT                                {ECO:0000303|PubMed:14976260}.
FT                                /FTId=VSP_012076.
FT   VARIANT      75     75       G -> V (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042387.
FT   VARIANT     141    141       S -> L (in HOMG1; impairs heterodimer
FT                                formation resulting in intracellular
FT                                retention; dbSNP:rs121912625).
FT                                {ECO:0000269|PubMed:12032568,
FT                                ECO:0000269|PubMed:14976260}.
FT                                /FTId=VAR_019963.
FT   VARIANT     338    338       M -> I (in dbSNP:rs56155062).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042388.
FT   VARIANT     708    708       L -> P (in HOMG1; loss of function; no
FT                                effect on cell membrane localization).
FT                                {ECO:0000269|PubMed:23942199}.
FT                                /FTId=VAR_071480.
FT   VARIANT     872    872       E -> G (in HOMG1; loss of function; no
FT                                effect on cell membrane localization).
FT                                {ECO:0000269|PubMed:23942199}.
FT                                /FTId=VAR_071481.
FT   VARIANT     948    948       F -> L (in dbSNP:rs13290391).
FT                                /FTId=VAR_052380.
FT   VARIANT    1007   1007       W -> C (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042389.
FT   VARIANT    1053   1053       Y -> C (in HOMG1; loss of function; no
FT                                effect on cell membrane localization).
FT                                {ECO:0000269|PubMed:23942199}.
FT                                /FTId=VAR_071482.
FT   VARIANT    1071   1071       N -> D (in dbSNP:rs2274922).
FT                                /FTId=VAR_019964.
FT   VARIANT    1143   1143       L -> P (in HOMG1; loss of function; no
FT                                effect on cell membrane localization).
FT                                {ECO:0000269|PubMed:23942199}.
FT                                /FTId=VAR_071483.
FT   VARIANT    1243   1243       H -> R (in dbSNP:rs55694430).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042390.
FT   VARIANT    1274   1274       Q -> R (in dbSNP:rs34608911).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042391.
FT   VARIANT    1393   1393       V -> I (in dbSNP:rs3750425).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019965.
FT   VARIANT    1584   1584       K -> E (in dbSNP:rs2274924).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019966.
FT   VARIANT    1663   1663       Q -> R (no effect on function or cell
FT                                membrane localization; dbSNP:rs55679040).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:23942199}.
FT                                /FTId=VAR_042392.
FT   VARIANT    1673   1673       L -> S (in dbSNP:rs56254742).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042393.
FT   VARIANT    1724   1724       T -> I (in dbSNP:rs56290308).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042394.
FT   VARIANT    1754   1754       S -> N (in HOMG1; loss of function; no
FT                                effect on cell membrane localization).
FT                                {ECO:0000269|PubMed:23942199}.
FT                                /FTId=VAR_071484.
FT   MUTAGEN    1804   1804       K->R: Abolishes kinase activity but does
FT                                not affect expression levels or binding
FT                                to RACK1. {ECO:0000269|PubMed:18258429}.
FT   MUTAGEN    1851   1851       T->A: Significantly decreases
FT                                autophosphorylation. Does not alter
FT                                binding to RACK1 but prevents inhibition
FT                                by RACK1. {ECO:0000269|PubMed:18258429}.
FT   MUTAGEN    1851   1851       T->D: Significantly decreases
FT                                autophosphorylation. Does not alter
FT                                binding to RACK1 or inhibition by RACK1.
FT                                {ECO:0000269|PubMed:18258429}.
SQ   SEQUENCE   2022 AA;  231708 MW;  59346B3BE3300466 CRC64;
     MKEQPVLERL QSQKSWIKGV FDKRECSTII PSSKNPHRCT PVCQVCQNLI RCYCGRLIGD
     HAGIDYSWTI SAAKGKESEQ WSVEKHTTKS PTDTFGTINF QDGEHTHHAK YIRTSYDTKL
     DHLLHLMLKE WKMELPKLVI SVHGGIQNFT MPSKFKEIFS QGLVKAAETT GAWIITEGIN
     TGVSKHVGDA LKSHSSHSLR KIWTVGIPPW GVIENQRDLI GKDVVCLYQT LDNPLSKLTT
     LNSMHSHFIL SDDGTVGKYG NEMKLRRNLE KYLSLQKIHC RSRQGVPVVG LVVEGGPNVI
     LSVWETVKDK DPVVVCEGTG RAADLLAFTH KHLADEGMLR PQVKEEIICM IQNTFNFSLK
     QSKHLFQILM ECMVHRDCIT IFDADSEEQQ DLDLAILTAL LKGTNLSASE QLNLAMAWDR
     VDIAKKHILI YEQHWKPDAL EQAMSDALVM DRVDFVKLLI EYGVNLHRFL TIPRLEELYN
     TKQGPTNTLL HHLVQDVKQH TLLSGYRITL IDIGLVVEYL IGRAYRSNYT RKHFRALYNN
     LYRKYKHQRH SSGNRNESAE STLHSQFIRT AQPYKFKEKS IVLHKSRKKS KEQNVSDDPE
     STGFLYPYND LLVWAVLMKR QKMAMFFWQH GEEATVKAVI ACILYRAMAH EAKESHMVDD
     ASEELKNYSK QFGQLALDLL EKAFKQNERM AMTLLTYELR NWSNSTCLKL AVSGGLRPFV
     SHTCTQMLLT DMWMGRLKMR KNSWLKIIIS IILPPTILTL EFKSKAEMSH VPQSQDFQFM
     WYYSDQNASS SKESASVKEY DLERGHDEKL DENQHFGLES GHQHLPWTRK VYEFYSAPIV
     KFWFYTMAYL AFLMLFTYTV LVEMQPQPSV QEWLVSIYIF TNAIEVVREI CISEPGKFTQ
     KVKVWISEYW NLTETVAIGL FSAGFVLRWG DPPFHTAGRL IYCIDIIFWF SRLLDFFAVN
     QHAGPYVTMI AKMTANMFYI VIIMAIVLLS FGVARKAILS PKEPPSWSLA RDIVFEPYWM
     IYGEVYAGEI DVCSSQPSCP PGSFLTPFLQ AVYLFVQYII MVNLLIAFFN NVYLDMESIS
     NNLWKYNRYR YIMTYHEKPW LPPPLILLSH VGLLLRRLCC HRAPHDQEEG DVGLKLYLSK
     EDLKKLHDFE EQCVEKYFHE KMEDVNCSCE ERIRVTSERV TEMYFQLKEM NEKVSFIKDS
     LLSLDSQVGH LQDLSALTVD TLKVLSAVDT LQEDEALLAK RKHSTCKKLP HSWSNVICAE
     VLGSMEIAGE KKYQYYSMPS SLLRSLAGGR HPPRVQRGAL LEITNSKREA TNVRNDQERQ
     ETQSSIVVSG VSPNRQAHSK YGQFLLVPSN LKRVPFSAET VLPLSRPSVP DVLATEQDIQ
     TEVLVHLTGQ TPVVSDWASV DEPKEKHEPI AHLLDGQDKA EQVLPTLSCT PEPMTMSSPL
     SQAKIMQTGG GYVNWAFSEG DETGVFSIKK KWQTCLPSTC DSDSSRSEQH QKQAQDSSLS
     DNSTRSAQSS ECSEVGPWLQ PNTSFWINPL RRYRPFARSH SFRFHKEEKL MKICKIKNLS
     GSSEIGQGAW VKAKMLTKDR RLSKKKKNTQ GLQVPIITVN ACSQSDQLNP EPGENSISEE
     EYSKNWFTVS KFSHTGVEPY IHQKMKTKEI GQCAIQISDY LKQSQEDLSK NSLWNSRSTN
     LNRNSLLKSS IGVDKISASL KSPQEPHHHY SAIERNNLMR LSQTIPFTPV QLFAGEEITV
     YRLEESSPLN LDKSMSSWSQ RGRAAMIQVL SREEMDGGLR KAMRVVSTWS EDDILKPGQV
     FIVKSFLPEV VRTWHKIFQE STVLHLCLRE IQQQRAAQKL IYTFNQVKPQ TIPYTPRFLE
     VFLIYCHSAN QWLTIEKYMT GEFRKYNNNN GDEITPTNTL EELMLAFSHW TYEYTRGELL
     VLDLQGVGEN LTDPSVIKPE VKQSRGMVFG PANLGEDAIR NFIAKHHCNS CCRKLKLPDL
     KRNDYSPERI NSTFGLEIKI ESAEEPPARE TGRNSPEDDM QL
//
